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The CRISPR Revolution:
What Editing Human DNA Reveals About the Patent System's DNA Robin Feldman 1 Imagine that genes in all life forms, including plant, animal, and human, could be easily edited. Like the search and replace function of a word processor, errors in an individual's genetic code could be repaired or replaced, creating the ability to edit out devastating diseasecausing errors, test medical treatments, and perform a variety of industrial tasks. The CRISPR revolution does not quite bring this futuristic vision fully into focus-but it is close.
Not since the invention that launched Genentech and the entire biotech industry has a life science invention offered such promise. And it is no exaggeration to say that if CRISPR lives up to that promise, the technology could well be one of the greatest life science inventions of all time. Gene editing techniques existed before, of course, but they were slow, inaccurate, and expensive. CRISPR technology can guide gene editing components to a particular spot so that 1 Harry & Lillian Hastings Professor and Director of the Institute for Innovation Law, University of California Hastings College of the Law. The Institute's Startup Legal Garage program matches early stage companies with students and supervising attorneys at outside law firms for free legal work. Caribou, which was founded by the University of California's CRISPR inventor group, was matched by the program in the company's early stages. The Institute receives no privileged or confidential information, but reading about the company spurred the author's interest in the science of CRISPR and its implications for the patent system. The author also notes the general affiliation of the University of California Hastings and the broader University of California system. I am grateful to Evan Frondorf for invaluable research assistance and to Shelley Ackerman and Nathan Kipniss for comments on prior drafts. I also wish to thank participants in the UCLA Program on Understanding Law, Science, and Evidence (PULSE) symposium on "Imagining the Legal Landscape: Technology and the Law in 2030" for their comments and reflections.
The CRISPR story defies both of these narratives. Companies are racing to develop commercial applications for the technology, and researchers are using the technology, even though it is not clear where they will have to go to get a license for it. The uncertainty exists because patents on the CRISPR technology are mired in a fight that will take years to emerge from the US Patent & Trademark Office, let alone work its way through any court proceedings.
No one is willing to sit on the sidelines, however. Commercialization is moving forward, and not on the patent system's timeline.
Rather than serving as an essential vehicle for commercialization, patents appear to be largely peripheral to the CRISPR scientific applications underway. Companies are letting the patent system work through its slow, awkward dance on the theory that when the drama has played out, they will work out whatever licenses are necessary. Thus, in the case of CRISPR, the patent system is not fully playing the role that patent theorists might expect; it is a somewhat embarrassing and irritating sideshow.
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This is not to suggest that the patent system is playing no role at all in the CRISPR Odyssey. As detailed below, two groups are fighting mightily to obtain the patent prizes.
Commercialization, however, is moving forward despite this pitched battle. Rather than serving as the vehicle for bringing forth products for society, the patent system most likely will play a back-end role of dividing up the spoils. 
I.
What is CRISPR?
CRISPR genome editing technologies are derived from the bacterial version of an immune system, which consists of short bacterial DNA sequences and CRISPR associated (Cas)
proteins. Together, these allow bacteria to recognize and destroy viruses. The acronym CRISPR stands for "clustered regularly-interspaced short palindromic repeats," and it is no wonder scientists developed a short form for that mouthful. The full name offers clues into how these sequences are structured within the bacterial genome. CRISPR consists of so-called "spacer"
sequences that are incorporated from viruses or other foreign entities. These spacer sequences are sandwiched in-between short, repeating sequences that read the same forward and backward. 6 These sequences form the CRISPR array, which serves as a memory of past infections.
CRISPR arrays are transcribed into RNAs, which are then processed into shorter RNAs termed CRISPR RNA (crRNA). 7 (RNA exists in all cells and acts principally as a messenger with instructions from DNA for the creation of proteins.) This "crRNA" pairs with another short RNA (tracrRNA) to activate and guide an enzyme to a viral or other foreign DNA sequence that has been identified by the crRNA. At this point, the enzyme goes to work at cleaving and destroying the offending DNA.
The existence of CRISPR sequences in bacteria had long been known, dating back to its 1980s discovery by Japanese researchers. 8 In 2005, a microbiologist showed that the "spacer DNA" located between the repeated sequences actually is made up of DNA incorporated from invading viruses, and in 2007, microbiologists working for a Danish food company found that CRISPR DNA were used as part of an immune response for the bacteria. These discoveries related to natural CRISPR processes were only the beginning. It became clear that CRISPR systems had extraordinary promise as a simple, revolutionary mechanism for gene editing -in all organisms, not just bacteria. Gene editing previously was a lengthy, inefficient process, using comparatively crude techniques such as breeding, turning off (or "knocking out") the expression of genes using special proteins, and imprecise DNA cleaving.
As one scientist told the New York Times Magazine, "In the past, it was a student's entire Ph.D.
thesis to change one gene." 10 By isolating the processes that bacteria use to attack viruses, CRISPR can modify multiple genes -in days.
As discussed above, CRISPR systems naturally require "CRISPR RNA (cRNA)" to pair with "tracrRNA" to activate the cutting enzyme. Scientists now have created a single RNA molecule that combines both RNA sequences (the fusion being termed a guide RNA), allowing the system to work in a wide variety of organisms. These guide RNAs then are introduced to cells alongside a particularly effective cutting enzyme called Cas9. For this reason, the research tool and gene editing system is sometimes referred to as CRISPR-Cas9.
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The power of the system is simple: a scientist can create a guide RNA tailored to a specific gene or DNA sequence, pair it with Cas9, and easily remove segments of DNA and replace them with new segments. Theoretically, even single base pairs -single building blocks of genes -can be excised and replaced. It is, as many have described it, equal to a word processor for life, capable of changing biology as we know it.
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As discussed infra, the timeline for CRISPR's development as a gene editing tool is complicated and disputed. 13 There is general agreement, however, that Jennifer Doudna, a ability to obtain its patent. 39 Interferences are relics of the patent regime prior to passage of the America Invents Act, in which the US moved from a first-to-invent system to a first-to-file system. Interferences are designed to determine who was the first to invent. 40 The USPTO granted Doudna's request for an interference proceeding on January 11, 2016, and the proceedings are underway with a variety of disputed claims pulled into the process. 41 The patent proceedings are likely to take years to resolve, including potential court appeals. 42 In the meantime, as the patent system lumbers on, innovation moves forward unabated. This is not the first time a major life science invention has marched to a different beat.
In the early 1970s, researchers from Stanford University and the University of California developed a genetic tool that would later give birth to the biotech industry. Stanley Cohen, Herbert Boyer, and Paul Berg used a purified enzyme to allow individual genes to be copied, moved, and studied. 43 The universities applied an unusual licensing strategy for what would become known as the Cohen-Boyer patents. Recognizing the revolutionary and far-reaching nature of the invention, licenses were given to large numbers of users at a relatively low price.
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The licensing approach encouraged the widespread use of the technology, launching an entire industry while creating a handsome return for university coffers. In addition, the Cohen-Boyer patent licenses were crafted in a form that has received considerable criticism in other contexts. Those who took a license paid a small fee up front with a promise of royalties from any eventual products manufactured with discoveries made by using the technology. 51 In modern terms, this could be characterized as a form of "reachthrough royalty." 52 Reach-through royalties are now strongly discouraged by the National
Institutes of Health because of their potential to over-burden products with too many layers of payments. 53 In addition, some, including this author, have asserted that reach-through royalties 49 constitute misuse of a patent. 54 Nevertheless, the Cohen-Boyer licensing program was extremely effective and had a legendary impact on science and innovation. As with the CRISPR story, Silicon Valley understood its own needs better than any patent theorists.
III. Implications of CRISPR for the Patent System
One could argue that the CRISPR patent saga is merely an echo of a patent system prior to the changes in the America Invents Act, and that the effects of the prior system will fade across time. CRISPR, indeed, may be one of the last interference proceedings ever seen. 55 Even with the America Invents Act's new system, however, no one would suggest that the patent system is a speedy and efficient endeavor in which clear, reliable outcomes are the norm. 56 Complaints frequently sound from the computer technology realm, in which innovation happens rapidly and inventions may be obsolete by the time the patents issue. There, patents run the risk of interfering with innovation, rather than fostering it. Nevertheless, the CRISPR experience shows that the life science industry is not immune to fast leaps forward and to innovations out of sync with the operation of the patent system and its theoretical underpinnings.
As described above, the patent system is intended to provide incentives for people to invest in creating and bringing forth innovations for the benefit of society. Patents are supposed to be a game of winner-takes-all, and the one who arrives first (whether it is the firstto-file or the first-to-invent) wins. In this vein, the structure of the patent system stands in contrast to that of other intellectual property regimes in which society recognizes rights of multiple parties to the chase. Thus, the patent system does not have extensive prior user rights, as found in trademark law. Nor does the patent system have independent creation defenses, as found in copyright law. In short, the patent system does not focus on partial rights for those who came close, but lost by a nose. The winner, and only the winner, is supposed to take all.
This design follows a fundamental theoretical vision deeply entwined in the patent system. The utilitarian vision of the patent system reflects the belief that assigning rights to inventions will ensure that brilliant ideas are translated into products for the benefit of society. 57 The patent system has no interest in knowledge for its own sake, which is derided in the historic patent literature as things of "mere curiosity." 58 Rather, the patent system focuses on incentivizing applied industrial products-what is known in the economic literature as "innovation" and somewhat similar to the notion of "translational" work in the life sciences. 59 In short, a winner-takes-all system is supposed to optimize the creation of viable commercial products for everyone to enjoy.
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The winner-takes-all construct fits particularly well within a theoretical framework that has been receiving considerable attention in the patent world in recent years. According to this theoretical perspective, the patent system needs to have early or additional protections to incentivize the investment necessary to ensure commercialization. Originating with Edmund
Kitch's famous "prospect theory" expounded in the 1970s, this call for earlier and enhanced protections is echoing in a variety of scholarship today-all focused on the concern that commercialization of ideas will not occur without such protections.
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A theoretical framework in which a winner takes all and that winner is crowed early in the process looks quite different from a framework that contemplates partial victories or sharing the spoils. Nevertheless, the patent system increasingly appears to be playing out the latter scenario. Rather than incentivizing the creation and development of innovation up front, the patent system frequently plays the role of dividing up the spoils at the end of the day. This is true not only for spectacular inventions such as CRISPR, which politely ignore the patent licensing system, but for many run of the mill patent cases.
For example, the patent litigation system looks more like bargaining than winner-takesall. Roughly three-quarters of all patent lawsuits never proceed to trial because they are either settled by the parties or dropped. 62 For the small percentage of patent lawsuits that proceed to trial and a judgment of infringement, many of those dollar awards are reduced by appellate judges or by post-trial settlement between the parties. 63 The same pattern holds true for patent demand letters, with estimates suggesting that more than 90% of patent demands never proceed to the courthouse steps because they are either dropped or settled. 64 Lawsuits and demands that settle clearly represent a bargaining result. In addition, one could argue that dropping a patent lawsuit or demand also represents a form of settlement from the perspective that one side of the potential bargain has given up and walked away. Nor do the parties seem to be operating according to pristine patent theory. At least for CRISPR, no one is waiting to see who will be the "winner of all." They are simply moving forward anticipating that bargaining eventually will sort everything out.
Many other startups formed from university research operate in an analogous manner, moving first and sorting out the licensing later. University contracts and policies may provide that the university owns whatever a faculty member "conceives of" or "reduces to practice" during the time that the faculty member is employed by the university. Thus, if professors want to start companies with inventions from their labs, they must get licenses from the university technology transfer office to do so. Many, however, move forward without resolving the licensing first. The licensing process is too slow, the company might never become viable, and it all can be sorted out in the end. Once again, the patent system's image-in which a single winner obtains full rights and coordinates licensing to commercialize the invention-does not correlate with what is happening on the ground.
include some form of compulsory licensing, one that might better reflect the post-hoc bargaining that currently takes place.
There are a variety of potential advantages of having an overt compulsory licensing system, rather than a cloaked bargaining system that flies under the radar. For example, companies would no longer be pressed into operating outside a lumbering patent system that cannot keep pace with their innovations. In addition, bringing the bargaining into the light would reduce the incentive to engage in patent holdup or to drop eye-popping demands on the table that must be stripped away over time, with high transactions costs for parties and the courts. 71 It might also coax the Supreme Court into allowing patent protection for a wider array of inventions, such as the medical diagnostic inventions that have been shut out of the system with recent decisions. 72 In an all-of-nothing system, the Court may be tempted to opt for nothing, rather than cutting off future innovators for 20 years. 73 Finally, when a system focuses on dividing up the spoils at the end of the battle, the little guy tends to lose. Some form of rationalized compulsory licensing might leave more room for small players and the disruptive innovation they can produce.
I have argued in the past, that given the lack of a shared conception for things that are new, the limitations of language, and problems related to fixation in time, a patent can never definitively identify the metes and bounds of the rights. Rather, under any set of rules we could derive, a patent will always provide an opportunity to bargain-a seat at the negotiating with certain rules in place. 74 Some form of compulsory license system, one that better reflects innovation realities, would also be consistent with this theoretical analysis.
Germ line changes are the most dangerous for any organic system because they risk unintended consequences. After all, the US innovation system is a key driver of the economy, and making fundamental changes to anything related to that system could be a perilous endeavor. Nevertheless, CRISPR provides a startling view of a patent system that is out of step.
When technological innovation is moving despite the patent system, not because of it, perhaps it is time to take a closer look. 74 See ROBIN FELDMAN, RETHINKING PATENT LAW 34, 211-212 (Harvard 2012).
